Table 3.
Progression-free/overall survival with combined angiostatic plus anti-inflammatory therapy
| Trial | Treatment | Median Progression-free/overall survival (months) | |||
|---|---|---|---|---|---|
| Angiostatic | Anti-inflammatory | % pretreated patients | Trial | Historical control (first- line) | |
| RCCC I | Capecitabine | Pio/Rofe | 39 | 4.7/16.2 | |
| RCCC II | Capecitabine | Pio/Eto/IFN-α | 21 | 11.5/25.6 | 11.0/n.a.(for sunitinib) |
| HRPC | Capecitabine | Pio/Eto/Dexa | 39 | 3.6/14.4 | n. a./17.5 (for taxotere) |
| Melanoma II | |||||
| Arm A | Trofosfamide | – | 63 | 1.2/8.2 | n.a./5.6 (for DTIC) |
| Arm B | Trofosfamide | Pio/Rofe | 60 | 2.0/18.8 | |
| Cholangiocellular carcinoma | Capecitabine | Pio/Rofe | 10 | 2.0/8.0 | PR plus stable disease 20–73% |
Pio pioglitazone, Rofe rofecoxib, Eto etoricoxib, RCCC renal clear cell carcinoma, HRPC hormone refractory prostate cancer, n.a. not available